Today’s Top Three in Pharma 021209

Just got back from the ePharma Summit in Philadelphia and it’s going to take a couple days to digest, catch up, write up, etc. But here are a few news items for your Thursday:

Two more pharma companies jump aboard YouTube with their own channels – this is a promising direction for companies getting their toes in the water with social media applications.

Promising Phase III data on Zometa’s efficacy in breast cancer reduction – A newly published study in The New England Journal of Medicine shows that in premenopausal women with early breast cancer administering Zometa® (zoledronic acid) along with post-surgery hormone therapy provided a reduction in risk of recurrence or death that was 36% beyond that achieved with hormone therapy alone.

Atacand and kidney failure prevention? Very interesting. And, will Sanofi’s Multaq make it to market this time?

Rumor mill – Sanofi and Biogen?

For the Record – a quick muse on how I really feel about the pharma industry…

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

.